SI3268385T1 - Kombinirana T-celična receptorska genska terapija raka proti na MHC I in MHC II omejenim epitopom tumorskega antigena NY-ESO-1 - Google Patents
Kombinirana T-celična receptorska genska terapija raka proti na MHC I in MHC II omejenim epitopom tumorskega antigena NY-ESO-1Info
- Publication number
- SI3268385T1 SI3268385T1 SI201630678T SI201630678T SI3268385T1 SI 3268385 T1 SI3268385 T1 SI 3268385T1 SI 201630678 T SI201630678 T SI 201630678T SI 201630678 T SI201630678 T SI 201630678T SI 3268385 T1 SI3268385 T1 SI 3268385T1
- Authority
- SI
- Slovenia
- Prior art keywords
- mhc
- eso
- combined
- gene therapy
- cell receptor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 108700042075 T-Cell Receptor Genes Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15159001.5A EP3067366A1 (en) | 2015-03-13 | 2015-03-13 | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| PCT/EP2016/055242 WO2016146505A1 (en) | 2015-03-13 | 2016-03-11 | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 |
| EP16712262.1A EP3268385B1 (en) | 2015-03-13 | 2016-03-11 | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3268385T1 true SI3268385T1 (sl) | 2020-07-31 |
Family
ID=52669528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201630678T SI3268385T1 (sl) | 2015-03-13 | 2016-03-11 | Kombinirana T-celična receptorska genska terapija raka proti na MHC I in MHC II omejenim epitopom tumorskega antigena NY-ESO-1 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10781243B2 (https=) |
| EP (3) | EP3067366A1 (https=) |
| JP (2) | JP6998211B2 (https=) |
| CN (2) | CN107428816B (https=) |
| AU (1) | AU2016232441B2 (https=) |
| CA (1) | CA2974955A1 (https=) |
| DK (1) | DK3268385T3 (https=) |
| ES (1) | ES2784315T3 (https=) |
| HU (1) | HUE049444T2 (https=) |
| PL (1) | PL3268385T3 (https=) |
| PT (1) | PT3268385T (https=) |
| SI (1) | SI3268385T1 (https=) |
| WO (1) | WO2016146505A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| SG10201803780UA (en) | 2013-11-04 | 2018-06-28 | Uti Lp | Methods and compositions for sustained immunotherapy |
| ES3055030T3 (en) | 2015-05-06 | 2026-02-09 | Uti Lp | Nanoparticle compositions for sustained therapy |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3354658A1 (en) * | 2017-01-25 | 2018-08-01 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases |
| US11236145B2 (en) | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| CN110945120B (zh) * | 2017-04-07 | 2025-04-18 | 优迪有限合伙公司 | 测量纳米药物中受体-配体相互作用的效力的测定 |
| CN109837245A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用 |
| EP3716949A4 (en) | 2017-11-29 | 2022-05-18 | UTI Limited Partnership | Methods of treating autoimmune disease |
| CN111819194B (zh) * | 2018-02-26 | 2024-06-04 | 基因医疗免疫疗法有限责任公司 | Nyeso t细胞受体(tcr) |
| CN110856751B (zh) | 2018-08-24 | 2024-12-03 | 杭州康万达医药科技有限公司 | 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用 |
| JP7748284B2 (ja) | 2019-03-04 | 2025-10-02 | ユニバーシティー ヘルス ネットワーク | Ｔ細胞受容体及びその使用方法 |
| EP3760217A1 (en) * | 2019-07-01 | 2021-01-06 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd5 specific t cell receptor cell or gene therapy |
| US20220273714A1 (en) * | 2019-07-19 | 2022-09-01 | The Regents Of The University Of California | T-cell receptors and methods of use thereof |
| CN112390875B (zh) * | 2019-08-16 | 2023-01-24 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的高亲和力t细胞受体 |
| CN113512124A (zh) * | 2020-04-10 | 2021-10-19 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv16的高亲和力tcr |
| CN112501269B (zh) * | 2020-12-15 | 2022-02-18 | 清华大学 | 一种快速鉴定高亲和力tcr抗原交叉反应活性的方法 |
| CN114121142B (zh) * | 2021-09-02 | 2023-10-31 | 四川大学华西医院 | 一种新型基因修饰增强型ny-eso-1特异型tcr-t模型构建方法及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000060055A1 (en) * | 1999-04-01 | 2000-10-12 | The Brigham And Women's Hospital, Inc. | Modified dendritic cells and uses therefor |
| EP2311950A1 (en) * | 2000-01-28 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| EP1409646B1 (en) * | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
| WO2003068800A2 (en) * | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Isolated peptides which bind to hla molecules and uses thereof |
| GB0411123D0 (en) * | 2004-05-19 | 2004-06-23 | Avidex Ltd | High-affinity NY-ESO T cell receptors |
| US7915036B2 (en) * | 2004-09-13 | 2011-03-29 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising T cell receptors and methods of use thereof |
| EP3173480A3 (en) * | 2007-03-05 | 2017-08-16 | International Institute of Cancer Immunology, Inc. | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
| CN101381402B (zh) * | 2008-10-20 | 2011-06-01 | 中国人民解放军第三军医大学 | Ny-eso-1肿瘤抗原模拟表位及其应用 |
| ES2635335T3 (es) | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| JP6378172B2 (ja) * | 2012-05-22 | 2018-08-22 | アメリカ合衆国 | マウス抗ｎｙ−ｅｓｏ−１ｔ細胞受容体 |
| US10377808B2 (en) | 2013-01-29 | 2019-08-13 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch | High avidity antigen recognizing constructs |
| RU2578009C2 (ru) * | 2013-05-08 | 2016-03-20 | Закрытое акционерное общество "ЕВРОГЕН" | Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках |
| CN106103711A (zh) * | 2013-11-21 | 2016-11-09 | 组库创世纪株式会社 | T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用 |
-
2015
- 2015-03-13 EP EP15159001.5A patent/EP3067366A1/en not_active Withdrawn
-
2016
- 2016-03-11 DK DK16712262.1T patent/DK3268385T3/da active
- 2016-03-11 US US15/558,021 patent/US10781243B2/en active Active
- 2016-03-11 EP EP16712262.1A patent/EP3268385B1/en active Active
- 2016-03-11 AU AU2016232441A patent/AU2016232441B2/en active Active
- 2016-03-11 SI SI201630678T patent/SI3268385T1/sl unknown
- 2016-03-11 HU HUE16712262A patent/HUE049444T2/hu unknown
- 2016-03-11 ES ES16712262T patent/ES2784315T3/es active Active
- 2016-03-11 JP JP2017548167A patent/JP6998211B2/ja active Active
- 2016-03-11 EP EP20150462.8A patent/EP3666793A3/en active Pending
- 2016-03-11 PT PT167122621T patent/PT3268385T/pt unknown
- 2016-03-11 CN CN201680015622.9A patent/CN107428816B/zh active Active
- 2016-03-11 CA CA2974955A patent/CA2974955A1/en active Pending
- 2016-03-11 WO PCT/EP2016/055242 patent/WO2016146505A1/en not_active Ceased
- 2016-03-11 CN CN202111497633.4A patent/CN114195883A/zh active Pending
- 2016-03-11 PL PL16712262T patent/PL3268385T3/pl unknown
-
2021
- 2021-06-15 JP JP2021099266A patent/JP2021151249A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3268385T3 (pl) | 2020-06-29 |
| EP3067366A1 (en) | 2016-09-14 |
| PT3268385T (pt) | 2020-04-08 |
| WO2016146505A1 (en) | 2016-09-22 |
| JP2021151249A (ja) | 2021-09-30 |
| CN107428816B (zh) | 2022-01-14 |
| AU2016232441B2 (en) | 2020-08-27 |
| US20180057560A1 (en) | 2018-03-01 |
| EP3268385B1 (en) | 2020-01-08 |
| US10781243B2 (en) | 2020-09-22 |
| EP3666793A2 (en) | 2020-06-17 |
| JP6998211B2 (ja) | 2022-02-04 |
| ES2784315T3 (es) | 2020-09-24 |
| HK1247212A1 (en) | 2018-09-21 |
| EP3268385A1 (en) | 2018-01-17 |
| HUE049444T2 (hu) | 2020-09-28 |
| JP2018509163A (ja) | 2018-04-05 |
| CN107428816A (zh) | 2017-12-01 |
| EP3666793A3 (en) | 2020-07-29 |
| DK3268385T3 (da) | 2020-04-06 |
| AU2016232441A1 (en) | 2017-08-10 |
| CA2974955A1 (en) | 2016-09-22 |
| CN114195883A (zh) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE049444T2 (hu) | Rák kombinált T-sejt receptoros génterápiája a NY-ESO-1 tumorantigén MHC I és MHC II által korlátozott epitópjai ellen | |
| IL294982B1 (en) | nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment | |
| IL265759A (en) | Therapeutic and diagnostic methods for cancer | |
| EP3548048A4 (en) | CANCER IMMUNOTHERAPY WITH CD8 + HIGHLY ENRICHED CHIMERIC ANTIGEN RECEPTOR T CELLS | |
| PL3707510T3 (pl) | Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych | |
| IL255372A0 (en) | Therapeutic and diagnostic methods for cancer | |
| HUE061874T2 (hu) | Anti-PD-1 antitestek és besugárzás kombinált alkalmazása a rák kezelésére | |
| HUE059484T2 (hu) | Az NY-ESO-1 tumorantigén - HLA-A | |
| PL3532607T3 (pl) | Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego | |
| IL273071A (en) | Treatment and diagnosis methods for cancer | |
| IL250043A0 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| EP3206987A4 (en) | Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | |
| IL248511A0 (en) | Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3 | |
| IL247066B (en) | Cancer immunotherapy by combining local and systemic immune stimulation | |
| PT3294770T (pt) | Métodos terapêuticos e diagnósticos para o cancro | |
| PT3142751T (pt) | Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células. | |
| ZA202102745B (en) | Anti-ptk7 immune cell cancer therapy | |
| ZA202102740B (en) | Anti-liv1 immune cell cancer therapy | |
| HUE043443T2 (hu) | Monoklonális antitestek rák és autoimmun betegségek diagnosztizálásában és terápiájában történõ alkalmazásra | |
| EP3271401A4 (en) | Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens | |
| SG11201701035SA (en) | Cancer diagnosis and therapy | |
| IL246607A0 (en) | Improved cellular preparations and methods for cancer treatment | |
| SG11201605784YA (en) | Cell surface prostate cancer antigen for diagnosis | |
| IL254228B (en) | Cell therapeutic agent for cancer treatment and combination therapy with same | |
| SG11201707949XA (en) | Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy |